Healthcare / BiotechnologyTaipei Exchange
$24.80
-0.20 (-0.80%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 22%
FCF escenarios
weak_data · normalized FCF $-30.4M · quality 65.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
26/100
D
Piotroski
0/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$1.2B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-15.9%
↓Gross Margin
99.1%
↑Debt/Equity
0.01
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+86.8%
FCF CAGR
—
FCF margin
-435.9%
FCF / Net income
1.11x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $16.3M · net income $-64.0M · FCF $-70.9M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $16.3M | $16.3M | $21.6M | $2.3M | $2.5M |
| Net Income | $-64.0M | $-64.0M | $-37.0M | $-28.1M | $-41.8M |
| EBITDA | $-60.9M | $-60.9M | $-32.5M | $-26.8M | $-40.9M |
| EPS | — | — | -1.12 | -12.32 | -18.35 |
| Gross Margin | 99.1% | 99.1% | 99.4% | 96.2% | 96.6% |
| Operating Margin | -358.5% | -358.5% | -198.4% | -1234.0% | -1554.4% |
| Net Margin | -393.5% | -393.5% | -171.1% | -1210.8% | -1675.9% |
| Balance Sheet | |||||
| Debt/Equity | 0.01 | 0.01 | 0.01 | -0.01 | -0.03 |
| Current Ratio | 47.95 | 47.95 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-70.9M | $-70.9M | $-30.4M | $-27.6M | $-44.3M |
| Returns | |||||
| ROE | -15.9% | -15.9% | -7.9% | 33.7% | 75.8% |
| Valuation | |||||
| P/B | 3.02 | 3.02 | 2.65 | — | — |
| Growth & Yield | |||||
| Revenue Growth | -24.7% | -24.7% | 831.3% | -7.1% | — |
| EPS Growth | — | — | 90.9% | 32.9% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-27.3%
Start / end P/E
n/dx → n/dx
EPS bridge
-1.12 → n/d
Residual
-27.3%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.